Yihongzi Company has obtained the notice of approval of the supplementary application for levocetirizine hydrochloride oral drops.

FAP, June 12 / PRNewswire-FirstCall-Asianet /-- poinsettia Pharmaceuticals, a wholly owned subsidiary, recently received a "notice of Drug Supplementary Application approval" for levocetirizine hydrochloride oral drops approved and issued by the State Drug Administration, agreeing to add the 20ml:100mg specification to the original approved 15ml:75mg specification. Issue the drug approval number. Levocetirizine hydrochloride oral drops are used in the treatment of allergic rhinitis and chronic idiopathic urticaria.